Literature DB >> 32614088

Acute Kidney Injury in Decompensated Cirrhosis Is Associated With Both Hypo-coagulable and Hyper-coagulable Features.

Alberto Zanetto1,2,3, Henry M Rinder4,5, Elena Campello6, Graziella Saggiorato6, Yanhong Deng7, Maria Ciarleglio7, Francis P Wilson8, Marco Senzolo3, Sabrina Gavasso6, Cristiana Bulato6, Paolo Simioni6, Guadalupe Garcia-Tsao1,2.   

Abstract

BACKGROUND AND AIMS: Recent evidence suggests that acute kidney injury (AKI) is the main predictor of postparacentesis bleeding in patients with cirrhosis. To assess the factors responsible for bleeding tendency in AKI, we performed a prospective study comparing all three aspects of hemostasis (platelets, coagulation, and fibrinolysis) in patients with decompensated cirrhosis with and without AKI. APPROACH AND
RESULTS: Primary hemostasis assessment included platelet aggregation and secretion (platelet function markers) and von Willebrand factor. Secondary hemostasis assessment included pro-coagulant (factor VIII and factor XIII) and anti-coagulant (protein C, protein S, and antithrombin) factors and thrombin generation. Tertiary hemostasis assessment included fibrinolytic factors and plasmin-antiplasmin complex. Eighty patients with decompensated cirrhosis were recruited (40 each with and without AKI). Severity of cirrhosis and platelet count were comparable between groups. Median serum creatinine was 1.8 mg/dL and 0.8 mg/dL in patients with and without AKI, respectively. At baseline, patients with cirrhosis and AKI had lower platelet aggregation and secretion, indicative of impaired platelet function (increased bleeding tendency), without differences in von Willebrand factor. Regarding coagulation factors, factor VIII was higher, whereas protein C, protein S, and antithrombin were all lower, which, together with increased thrombin generation, indicate hypercoagulability. In contrast, factor XIII was lower in AKI (increased bleeding tendency). Finally, while both hypofibrinolytic and hyperfibrinolytic changes were present in AKI, a higher plasmin-antiplasmin complex indicated a hyperfibrinolytic state. After AKI resolution (n = 23 of 40), platelet function and coagulation improved to levels observed in patients with cirrhosis patients without AKI; however, fibrinolysis remained hyperactivated.
CONCLUSIONS: In patients with decompensated cirrhosis, AKI is associated with both hypocoagulable and hypercoagulable features that can potentially increase the risk of both bleeding and thrombosis.
© 2020 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32614088      PMCID: PMC8672302          DOI: 10.1002/hep.31443

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  43 in total

1.  Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis.

Authors:  T Lisman; F W Leebeek; L O Mosnier; B N Bouma; J C Meijers; H L Janssen; H K Nieuwenhuis; P G De Groot
Journal:  Gastroenterology       Date:  2001-07       Impact factor: 22.682

2.  Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases.

Authors:  Guadalupe Garcia-Tsao; Juan G Abraldes; Annalisa Berzigotti; Jaime Bosch
Journal:  Hepatology       Date:  2016-12-01       Impact factor: 17.425

3.  Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests.

Authors:  Armando Tripodi; Francesco Salerno; Veena Chantarangkul; Marigrazia Clerici; Massimo Cazzaniga; Massimo Primignani; Pier Mannuccio Mannucci
Journal:  Hepatology       Date:  2005-03       Impact factor: 17.425

4.  Balanced haemostasis with both hypo- and hyper-coagulable features in critically ill patients with acute-on-chronic-liver failure.

Authors:  Caleb Fisher; Vishal C Patel; Sidsel Hyldgaard Stoy; Arjuna Singanayagam; Jelle Adelmeijer; Julia Wendon; Debbie L Shawcross; Ton Lisman; William Bernal
Journal:  J Crit Care       Date:  2017-08-17       Impact factor: 3.425

5.  Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients.

Authors:  S Schulman; C Kearon
Journal:  J Thromb Haemost       Date:  2005-04       Impact factor: 5.824

6.  Approach to the assessment of platelet function: comparison between optical-based platelet-rich plasma and impedance-based whole blood platelet aggregation methods.

Authors:  Anna M Dyszkiewicz-Korpanty; Eugene P Frenkel; Ravindra Sarode
Journal:  Clin Appl Thromb Hemost       Date:  2005-01       Impact factor: 2.389

7.  Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis.

Authors:  Richard Moreau; Rajiv Jalan; Pere Gines; Marco Pavesi; Paolo Angeli; Juan Cordoba; Francois Durand; Thierry Gustot; Faouzi Saliba; Marco Domenicali; Alexander Gerbes; Julia Wendon; Carlo Alessandria; Wim Laleman; Stefan Zeuzem; Jonel Trebicka; Mauro Bernardi; Vicente Arroyo
Journal:  Gastroenterology       Date:  2013-03-06       Impact factor: 22.682

8.  Bacterial infection in cirrhosis impairs coagulation by a heparin effect: a prospective study.

Authors:  Paolo Montalto; Jiannis Vlachogiannakos; Dominic J Cox; Sabrina Pastacaldi; David Patch; Andrew K Burroughs
Journal:  J Hepatol       Date:  2002-10       Impact factor: 25.083

9.  Lack of increased bleeding after paracentesis and thoracentesis in patients with mild coagulation abnormalities.

Authors:  P A McVay; P T Toy
Journal:  Transfusion       Date:  1991-02       Impact factor: 3.157

Review 10.  Acute kidney injury in cirrhosis.

Authors:  Guadalupe Garcia-Tsao; Chirag R Parikh; Antonella Viola
Journal:  Hepatology       Date:  2008-12       Impact factor: 17.425

View more
  6 in total

1.  Fibrin clot quality in acutely ill cirrhosis patients: Relation with outcome and improvement with coagulation factor concentrates.

Authors:  Annabel Blasi; Vishal C Patel; Eva N H E Spanke; Jelle Adelmeijer; Marilena Stamouli; Ane Zamalloa; Eleanor Corcoran; Andrea Calvo; Javier Fernandez; William Bernal; Ton Lisman
Journal:  Liver Int       Date:  2021-12-20       Impact factor: 8.754

2.  Reduced Clot Stability by Thromboelastography as a Potential Indicator of Procedure-Related Bleeding in Decompensated Cirrhosis.

Authors:  Alberto Zanetto; Henry M Rinder; Marco Senzolo; Paolo Simioni; Guadalupe Garcia-Tsao
Journal:  Hepatol Commun       Date:  2020-12-12

3.  More Pronounced Hypercoagulable State and Hypofibrinolysis in Patients With Cirrhosis With Versus Without HCC.

Authors:  Marco Senzolo; Paolo Simioni; Alberto Zanetto; Elena Campello; Cristiana Bulato; Sabrina Gavasso; Graziella Saggiorato; Sarah Shalaby; Luca Spiezia; Umberto Cillo; Fabio Farinati; Francesco Paolo Russo; Patrizia Burra
Journal:  Hepatol Commun       Date:  2021-08-16

4.  Association of Heparin-Like Effect, Factor VII/XIII Deficiency and Fibrinolysis with Rebleeding Risk in Cirrhosis with Acute Variceal Bleeding.

Authors:  Madhumita Premkumar; Rohit Mehtani; Anand V Kulkarni; Ajay Kumar Duseja; Arka De; Sunil Taneja; Virendra Singh; Nipun Verma; Jasmina Ahluwalia; Kamal Kajal; Smita Divyaveer; Akash Roy; Akash Gandotra; Narender Kalson; Kushal Kekan; Harmanpreet Kaur; Harpreet Kaur
Journal:  Dig Dis Sci       Date:  2022-08-19       Impact factor: 3.487

5.  Assessing Clinically Meaningful Hypercoagulability after COVID-19 Vaccination: A Longitudinal Study.

Authors:  Elena Campello; Cristiana Bulato; Chiara Simion; Luca Spiezia; Claudia Maria Radu; Sabrina Gavasso; Francesca Sartorello; Graziella Saggiorato; Patrizia Zerbinati; Mariangela Fadin; Daniela Tormene; Paolo Simioni
Journal:  Thromb Haemost       Date:  2022-03-04       Impact factor: 6.681

6.  VWF/ADAMTS13 Imbalance, But Not Global Coagulation or Fibrinolysis, Is Associated With Outcome and Bleeding in Acute Liver Failure.

Authors:  Ellen G Driever; R Todd Stravitz; Jingwen Zhang; Jelle Adelmeijer; Valerie Durkalski; William M Lee; Ton Lisman
Journal:  Hepatology       Date:  2021-05       Impact factor: 17.425

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.